Cutting-edge issues in sympathetic ophthalmia approach and six case reports: a T cell-mediated autoimmune response

Arq Bras Oftalmol. 2024 May 13;87(4):e20220142. doi: 10.5935/0004-2749.2022-0142. eCollection 2024.

Abstract

Sympathetic ophthalmia is a rare and potentially devastating bilateral diffuse granulomatous panuveitis. It is caused by surgical or non-surgical eye injuries and is an uncommon and serious complication of trauma. It is diagnosed clinically and supported by imaging examinations such as ocular ultrasonography and optical coherence tomography. Its treatment consists of immunosuppressive therapy with steroids and sometimes steroid-sparing drugs, such as cyclosporine, azathioprine, cyclophosphamide, and mycophenolate mofetil. Fast and effective management with systemic immunosuppressive agents allows for disease control and achievement of good visual acuity in the sympathizing eye. By contrast, enucleation should be considered only in situations where the injured eye has no light perception or in the presence of severe trauma. In addition to a bibliographic review of this topic, we report six cases involving different immunosuppressive and surgical treatment modalities.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Female
  • Humans
  • Immunosuppressive Agents* / therapeutic use
  • Male
  • Middle Aged
  • Ophthalmia, Sympathetic* / drug therapy
  • T-Lymphocytes / immunology
  • Tomography, Optical Coherence / methods
  • Visual Acuity